<DOC>
	<DOCNO>NCT01522833</DOCNO>
	<brief_summary>With roughly 80 % cancer patient receive oncology care community setting , investigator propose sample community-based center evaluate percentage epidermal growth factor receptor ( EGFR ) -wild type patient gain benefit erlotinib ass clinical characteristic associate erlotinib-responders . Additionally , biopsy specimen enrol patient case EGFR-wt evaluate via exploratory genetic analysis correlate marker .</brief_summary>
	<brief_title>Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months Longer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients must NSCLC . Patients must receive erlotinib ( singleagent ) six month longer NSCLC second/third line set maintenance therapy . Patients must tissue available EGFRmutation status test ( previously perform ) EGFRmutation status test result available . Patients must tissue available exploratory genetic analysis . Patients must clinical information , treatment response data outcome data available review . Patients must decease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSLCL</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
</DOC>